Company Management

GlyProVac

Biotechnology Research Dk 12 employees

Employees: 12
Contacts: 1
Emails: 1

glyprovac.com LinkedIn Crunchbase

GlyProVac Overview

Headquarters: Dk
Website: glyprovac.com
Industry: Biotechnology Research
Employees: 12
Founded: 2018
Funding: 467.0K
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Mass Spectrometry Microbiology Molecular Biology Bacterial Pathogens

About GlyProVac

GlyProVac has via its proprietary platform technology, BEMAP, discovered that 1) O-linked protein glycosylation is a surprisingly abundant post translational modification in bacterial, 2) glycoproteins are linked to increased immunogenicity. GlyProVac aim to be the first to explore and exploit this novel class of antigens as candidates for vaccine development. The GlyProVac lead YghJ/SslE/AcfD is a conserved protein with a known biological function and has vaccine potential not only in ETEC but also in UPEC. Using BEMAP, GlyProVac has identified 59 glycosylated residues in YghJ. We are in the PoC phase and currently work to establish that glycosylated YghJ elicit a more protective immune response compared to the non-glycosylated version.

GlyProVac Contact Details

People in AeroLeads: 2
With contact data: 1
Email contacts: 1; 50.0% coverage

GlyProVac Org Chart

Sample employees and titles

Name	Title	Location	Contact
Wian De Jongh	CEO at Adaptvac	Copenhagen, Capital Region of Denmark, Denmark	Email
Ann Zahle Andersen	Co-founder and COO at Glyprovac Aps	Odense, Region of Southern Denmark, Denmark	View